The following video is part of our "Motley Fool Conversations" series, in which consumer goods editor and analyst Austin Smith discusses topics across the investing world.
In today's edition, Austin talks about why he's currently holding on to his shares of Pfizer. Despite losing its extremely important patent on Lipitor, the company has three new drug launches during 2011-2012 that should offset any losses. The company is the biggest of the big pharma giants, and has a cash balance that dwarfs its competitors'. One of the things you're buying with Pfizer today is upcoming internal efficiencies. The company has made cutting $4 billion in costs through 2012 a goal. Not only that, the sale of its animal health and nutritional business could provide cash for more dividends, share repurchases, or blockbuster drug development.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time thisarticle was published Austin Smith owns shares of Pfizer. The Motley Fool owns shares of Johnson & Johnson.Motley Fool newsletter services recommendJohnson & Johnson and Pfizer. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.